Ligand Pharmaceuticals LGND Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:EmployeeRelatedLiabilitiesCurrent.
The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ligand Pharmaceuticals's accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ligand Pharmaceuticals's accrued expenses?
- Ligand Pharmaceuticals (LGND) reported accrued expenses of $3.55M in Q1 2026.
- How has Ligand Pharmaceuticals's accrued expenses changed year-over-year?
- Ligand Pharmaceuticals's accrued expenses increased by 87.9% year-over-year, from $1.89M to $3.55M.
- What is the long-term trend for Ligand Pharmaceuticals's accrued expenses?
- Over 5 years (2020 to 2025), Ligand Pharmaceuticals's accrued expenses has grown at a -19.2% compound annual growth rate (CAGR), from $18.53M to $6.39M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.